Stran je namenjena samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji.

Search

Menu

Close

PrijavaOdjava
Naša zdravilaTerapevtska področjaMedia CenterMedia CenterDogodkiGradivaVideo vsebinePovežimo sePovežimo seKontaktirajte nasMedicinske informacije družbe Pfizer

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Deliver the broadest serotype coverage for babies1-3Prevenar 20™ helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1 Serotype coveragePrevenar 20™ delivers the most serotype coverage in a pneumococcal conjugate vaccine (PCV) for babies, adding 7 serotypes to Prevenar 13®1-3

Prevenar 20™ and Prevenar 13® will only help protect against Streptococcus pneumoniae serotypes in their respective vaccines.1,2

Learn more about serotypes covered by Prevenar 20™

Prevenar 20™ covers the most serotypes causing cases of invasive pneumococcal disease (IPD) in babies in [Country]1-3,5

Prevenar 20™ helps protect against 20 S. pneumoniae serotypes in the vaccine that are responsible for more disease in [Country nationality] babies than serotypes covered by any other PCV.1-3,5

There are no studies that compare the efficacy of Prevenar 20™ and PCV15.

The 13-serotype vaccine provides coverage for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The 15-serotype vaccine provides coverage for all serotypes covered by the 13-serotype vaccine and the additional serotypes 22F and 33F. The 20-serotype vaccine provides coverage for all serotypes covered by the 15-serotype vaccine and the additional serotypes 8, 10A, 11A, 12F, and 15B.1-3
PCV15=15-valent pneumococcal conjugate vaccine.Effectiveness20+ years of demonstrated effectiveness in IPD prevention in young children with Prevenar‡ vaccines2

Prevenar‡ vaccines have demonstrated effectiveness at helping to protect against vaccine-type IPD in young children for nearly 2 decades in [Country].5,7

Since the introduction of Prevenar® (PCV7) in 2006 and Prevenar 13® in 2010, the serotype coverage provided by these vaccines has reduced vaccine-type IPD in children under 2 years of age by about 87%.5,7

 Prevenar 20™ delivers a new level of Prevenar‡ protection for babies1

Prevenar 20™ elicited a robust immune response after [__] doses in a phase 3 clinical study and is expected to perform similarly to Prevenar 13®.1

Review Prevenar 20™ coverage and Prevenar‡ effectiveness data

Prevenar includes Prevenar® and Prevenar 13®. In [Country], Prevenar® (PCV7) was available from 2001 to 2010, and Prevenar 13® has been available since 2010.2,4,10The GNRCS has been collecting IPD isolates from children in Germany since 1997, serotyped  using the Neufeld Quellung reaction.5In Germany Prevenar® (PCV7) was available in 2001 and recommended by STIKO for children with an increased risk for pneumococcal disease only. Universal vaccination of all children <2 years of age was recommended in 2006. In 2009, Prevenar® (PCV7) was replaced by the higher-valent vaccine Prevenar 13®.7
GNRCS=German National Reference Center for Streptococci; PCV7=7-valent pneumococcal conjugate vaccine;
STIKO=Standing Committee on Vaccination.[Local body] Recommendation & dosing[Local body]-recommended Prevenar 20™ dosing for all groups ≤18 years of age1,9,11 The United States Advisory Committee on Immunization Practices (ACIP) recommends transitioning babies to Prevenar 20™ at any point of a series started with Prevenar 13®9

Learn more about dosing for
Prevenar 20™

¶Given at least 8 weeks after last PCV dose.

Administration & storagePrevenar 20™ is administered the same way as Prevenar 13®1,2

Prevenar includes Prevenar 13® and Prevenar 20™. For paediatric use in [Country], Prevenar 13® has been available since 2010 and Prevenar 20™ since 2023.1,2,10

Storage and handling for Prevenar 20™ Stability data indicate that the vaccine is stable for 96 hours when stored at temperatures from 8°C to 25°C, or 72 hours when stored at temperatures from 0°C to 2°C. At the end of these time periods Prevenar 20™ should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.1Ordering & reimbursementOrder Prevenar 20™

[Markets to include local details]

Reimbursement

[Markets to include local details]

References:Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Prevenar® (Pneumococcal 7-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2011.van der Linden M, Itzek A, Perniciaro S, Imöhl M. Invasive pneumococcal disease among children in Germany, ten years after PCV13 introduction. Poster presented online at: The European Society for Paediatric Infectious Diseases 2020 Virtual Meeting; October 28, 2020.van der Linden M, Perniciaro S, Imöhl M. Invasive pneumococcal disease among children in Germany, ten years after PCV13 introduction. Abstract P0325 presented online at: The European Society for Paediatric Infectious Diseases 2020 Virtual Meeting; October 28, 2020.van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257.Chapman R, Sutton K, Dillon-Murphy D, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis. Vaccine. 2020;38(45):7138-7145.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.Local approval dates.About Order Prevenar 20™ See how Loading Robust immune response with Prevenar 20™ after [__] doses1 Review trial results Loading [Local body] recommends Prevenar 20™ for routine infant vaccination9 Learn more Loading
PP-PNR-GLB-0425 March 2024
PfizerPro računPfizerPro račun

Za dostop do dodatnih gradiv, vsebin in prejemanje sporočil o zdravilih in cepivih družbe Pfizer

VpisRegistracijaRačunOdjava

To spletno mesto je namenjeno samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji. Če se uvrščate med širšo javnost in bi želeli dostopati do informacij o določenem zdravilu, se, prosimo, obrnite na vašega zdravnika ali farmacevta.

 

To spletno stran vam ponuja Pfizer, podružnica Ljubljana.

 

Avtorske pravice 2022 Pfizer, podružnica Ljubljana. Vse pravice pridržane.


Davčna številka: SI 17966086

PP-UNP-SVN-0142, datum priprave: september 2023
Zapuščate PfizerPro
​
Zapuščate spletno mesto, ki ga upravlja Pfizer. Povezave do vseh zunanjih spletnih mest so na voljo kot vir za naše obiskovalce. Pfizer ne prevzema odgovornosti za vsebino spletnih mest, ki niso v lasti in upravljanju družbe Pfizer.
 
PP-UNP-SVN-0142
datum priprave: september 2023
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​